Abstracts tagged "anti-TNF therapy and infliximab"

Abstract Number: 1269 • 2019 ACR/ARP Annual Meeting
Effective Treatment of TNFα Inhibitors in Chinese Patients with Blau Syndrome
Jing Chen ¹, Yi Luo ¹, Mengzhu Zhao ¹, Di Wu ¹, Yunjiao Yang ², Wen Zhang ³ and Min Shen¹, ¹Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Beijing, China (People's Republic), ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China (People's Republic)
Background/Purpose: Blau syndrome (BS) is a rare dominantly inherited autoinflammatory disorder associated with mutations in the NOD2 gene. BS is mainly seen in Caucasian patients.…
Abstract Number: 715 • 2016 ACR/ARHP Annual Meeting
Are Patients with Ankylosing Spondylitis Willing to Pay for Treatment with Infliximab?
Casper Webers^1,2, Ivette Essers^1,2, Astrid van Tubergen^1,2, Jürgen Braun³, Frank Heldmann⁴, Xenofon Baraliakos⁵ and Annelies Boonen^2,6, ¹Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ²School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Zeisigwaldkliniken Bethanien, Chemnitz, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: In view of the continuous pressure of biologicals on healthcare budgets, it is essential to assess the value of biologicals for patients from different…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].